Gain Therapeutics (GANX) Fundamental Analysis: Revenue, Earnings & Valuation

4.94 / 10

Netural

Fundamental score is 4.9/10 (moderate). Strengths include strong Cash‑MV, high inventory turnover, favorable cost‑of‑sales ratio and solid PB‑ROE. Weak points are negative Asset‑MV, Revenue‑MV and low gross profit margin, indicating selective quality.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score1/3

Weight13.54%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.50%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.96%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.27%

1M Return-0.63%

PB-ROE

Value3.41

Score3/3

Weight28.17%

1M Return9.74%

Income tax / Total profit (%)

Value21.05

Score2/3

Weight2.40%

1M Return1.04%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.31%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.39%

1M Return4.32%

Asset-MV

Value-0.49

Score0/3

Weight7.05%

1M Return2.69%

Cash-MV

Value-0.09

Score2/3

Weight15.95%

1M Return5.94%

Is GANX undervalued or overvalued?

GANX scores 4.94/10 on fundamentals and holds a Fair valuation at present. Backed by its -155.66% ROE, 0.00% net margin, -4.06 P/E ratio, 4.41 P/B ratio, and 31.46% earnings growth, these metrics solidify its Netural investment rating.